Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study

被引：1
|
作者：
Simonelli, M. [1 ]
Lorusso, D. [2 ]
Homicsko, K. [3 ,4 ]
Seguy, F. [5 ]
Kinder, M. [6 ]
Liu, Q. [7 ]
Croft, E. [8 ]
Kitano, S. [9 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol, Rozzano, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS Rome & H, Gynaecol Oncol Unit, Milan, Italy
[3] UNIL, Ludiwg Inst Canc Res, Oncol Dept, Lausanne, Switzerland
[4] CHU Vaudois, Lausanne, Switzerland
[5] Incyte Biosci Int Sarl, Clin Dev, Morges, Switzerland
[6] Incyte Corp, Translat Sci, Wilmington, DE USA
[7] Incyte Corp, Biostats, Wilmington, DE USA
[8] Incyte Corp, Early Clin Dev, Wilmington, DE USA
[9] Canc Inst Hosp JFCR, Dept Adv Med Dev, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.684
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617MO
引用
收藏
页码：S495 / S495
页数：1
相关论文
共 50 条
  • [41] A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas
    Infante, Jeffrey R.
    Shapiro, Geoffrey
    Witteveen, Petronella
    Gerecitano, John F.
    Ribrag, Vincent
    Chugh, Rashmi
    Issa, Isra
    Chakraborty, Abhijit
    Matano, Alessandro
    Zhao, Xumei
    Parasuraman, Sudha
    Cassier, Phillipe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] A phase I study (CA180021-Segment 2) of dasatinib in patients (pts) with advanced solid tumors
    Johnson, F. M.
    Chiappori, A.
    Burris, H., III
    Rosen, L.
    McCann, B.
    Luo, F. R.
    Mayfield, S.
    Palme, H.
    Platero, J.
    Blackwood-Chirchir, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A phase I study of flavopiridol using an alternative schedule in patients (pts) with advanced solid tumors
    Ramaswamy, B.
    Phelps, M.
    Baiocchi, R.
    Bekaii-Saab, T.
    Wilkins, D.
    Arbogast, D.
    Campbell, A.
    Doyle, A. L.
    Grever, M.
    Shah, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] A phase I dose escalation study to assess the safety tolerability and pharmacokinetics of ETS2101 in patients (pts) with advanced solid tumours
    Plummer, R.
    Anthoney, A.
    Evans, J.
    Haris, N.
    D'Archangelo, M.
    Slater, S.
    Campbell, S.
    Brindley, C.
    Self, S.
    McKeown, P.
    Lavin, S.
    Hynes, D.
    Flores, M. V.
    Pedret-Dunn, A.
    Laffranchi, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S58 - S59
  • [45] Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study
    Reid, T. R.
    Takimoto, C. H.
    Verschraegen, C. F.
    Sarantopoulos, J.
    Cheung, W.
    Allen-Freda, E.
    Li, J.
    Xu, Y.
    Ko, J.
    Johri, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Phase I study of WNT974+spartalizumab in patients (pts) with advanced solid tumors
    Janku, Filip
    de Vos, Filip
    de Miguel, Maria
    Forde, Patrick
    Ribas, Antoni
    Nagasaka, Misako
    Argiles, Guillem
    Arance, Ana Maria
    Calvo, Aitano
    Giannakis, Marios
    Melendez, Maritza
    Gong, Jiachang
    Szpakowski, Sebastian
    Kan, Rebecca
    Moody, Susan E.
    De Jonge, Maja
    CANCER RESEARCH, 2020, 80 (16)
  • [47] A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.
    Javle, Milind M.
    Bridgewater, John A.
    Gbolahan, Olumide B.
    Jungels, Christiane
    Cho, May Thet
    Papadopoulos, Kyriakos P.
    Thistlethwaite, Fiona C.
    Canon, Jean-Luc Re
    Cheng Lulu
    Ioannidis, Sonia
    Gogov, Sven
    Aung, Naing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
    Gan, Hui K.
    Millward, Michael
    Hua, Ye
    Qi, Chuan
    Sai, Yang
    Su, Weiguo
    Wang, Jian
    Zhang, Lilin
    Frigault, Melanie M.
    Morgan, Shethah
    Yang, Liu
    Lickliter, Jason D.
    CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4924 - 4932
  • [49] Phase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors.
    Senellart, Helene
    Bennouna, Jaafar
    Isambert, Nicolas
    De-Montserrat, Helene
    Squiban, Patrick J.
    Tschoepe, Inga
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345